What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Zanubrutinib has not been directly compared in a clinical trial with standard care, which limits the strength of the evidence. An indirect comparison suggests that zanubrutinib increases progression-free survival and overall survival compared to standard care, but the lack of direct evidence and the immature survival data introduce significant uncertainty.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for zanubrutinib are within the range that NICE considers acceptable for Healthcare resources, indicating a clear cost-effective profile under common thresholds.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee acknowledged the significant negative impact of marginal zone lymphoma on quality of life, emphasizing that quality of life is as important as living longer. While specific HRQoL data were not detailed, the recognition of this aspect suggests a moderate benefit in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of zanubrutinib appears acceptable, with manageable adverse events. The committee did not identify significant safety concerns that would undermine the treatment’s value.
Was the drug compared against what payers expect? — Comparator Selection
The committee agreed with the company’s positioning of zanubrutinib against appropriate comparators, including rituximab with or without chemotherapy, which aligns with current treatment practices.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a younger population than typically seen in the Healthcare, raising concerns about representativeness. However, the committee acknowledged that the patient characteristics from the HMRN registry were largely representative of standard care.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Zanubrutinib is an oral treatment that fits well into the existing care pathway, requiring minimal adjustments for integration into clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The committee noted that zanubrutinib’s cost is manageable and aligns with planning, indicating a notable but justifiable cost burden with proportional benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from phase 2 trials, which introduces limitations and uncertainty. The committee noted concerns about the immaturity of survival data and the indirect comparison methodology.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the representativeness of trial populations and the long-term extrapolations of survival data. The committee highlighted these uncertainties as critical in their decision-making process.
